alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 32.1





CERTIFICATION OF CHIEF EXECUTIVE OFFICER


PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





I, Jason Smart,  Chief  Executive  Officer  of Makeover Corporation of America  (the "Company"),  hereby  certify,  pursuant to 18 U.S.C.  Section  1350,  as adopted pursuant  to  Section  906  of  the  Sarbanes-Oxley  Act of  2002,  that,  to my knowledge:





(1) The  Company's  Quarterly  Report on Form 10-Q for the quarter  ended September 30, 2010, as filed with the Securities and Exchange  Commission on the date hereof (the  "Report"),  fully  complies with the  requirements  of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2)  The  information  contained  in the  Report  fairly  presents,  in all material  respects,  the  financial  condition  and results of operations of the Company.




/s/ Jason SmartJason SmartChief Executive Officer





Date: November 15, 2010





This  certification  accompanies  the  Report  pursuant  to  Section  906 of the Sarbanes-Oxley  Act of 2002 and  shall not be deemed  filed by the  Company  for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.





A signed  original of this written  statement  required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the  electronic  version of this written  statement required by Section 906,  has been  provided to the Company and will be retained by the Company and furnished to the  Securities  and Exchange  Commission or its staff upon request.
**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

The Board of Directors

Del Monte Foods Company: 

Weconsent to the incorporation by reference in the registration statements (Nos. 333-40867, 333-52226, 333-38394, 333-34280, 333-79315, 333-102702, 333-102700, 333-102006, 333-134898, and 333-147239) on Form S-8 of Del Monte Foods Company (theCompany) of our reports dated June 25, 2008, with respect to the consolidated balance sheets of Del Monte Foods Company and subsidiaries as of April 27, 2008 and April 29, 2007, and the related consolidated statements of income,stockholders’ equity and comprehensive income, and cash flows for each of the years in the three-year period ended April 27, 2008, and the effectiveness of internal control over financial reporting as of April 27, 2008, which reportsappear in the April 27, 2008 annual report on Form 10-K of Del Monte Foods Company (“10-K”), and to the reference to our firm under the heading “Selected Financial Data” in the 10-K. 

/s/ KPMG LLP 

San Francisco, California 

June 25, 2008
Rockingham,

No. 4666.

#### John Thomas Diamond, Jr. *v.*Frances Lorraine Diamond.

Argued June 4, 1958.

Decided June 20, 1958.

*339
      *Arthur J. Reinhart*(orally), for the plaintiff.

The defendant did not appear.

Blandin, J.

In the present situation the gravamen of the petition is that the defendant falsely represented to the plaintiff that she was pregnant and that she had never previously been married, both of which statements were false and made to induce him to wed her. The weight of authority is that false representations as to pregnancy, made for the purpose of persuading one to enter into the marriage relation, are not cause for annulment. 35 Am. Jur., Marriage, *s.*138. This is especially true when the parties had relations prior to marriage. 15 A. L. R. (2d) anno. 706, 726-728. Likewise the majority view is that concealment of a previous marriage dissolved by death or divorce is no ground for annulment. *Cassin*v. *Cassin,*264 Mass. 28; 35 Am. Jur., *supra, s.*158. It is true that these authorities are not controlling here and also that this marriage was never consummated, which is a factor, although not a decisive one, to be considered. Our courts as well as those of other jurisdictions, generally speaking, have granted annulment only with extreme caution. *Heath*v. *Heath,*85 N. H. 419, recently affirmed in *Patey*v. *Peaslee,*99 N. H. 335, requires fraud “making impossible the performance of the duties and obligations of [marriage] ... or rendering its assumption and continuance dangerous to health or life.” *Id.,*429. The reason for this as stated in the *Heath*opinion is that since dissolution of marriage by divorce may be granted only on statutory grounds, the courts in decreeing dissolution by nullity are in a sense invading the legislative province and this is proper solely when public opinion unequivocally demands it.

In the present situation, unfortunate though it may be, it seems clear to us that we cannot say the alleged fraud is such that a “persistent and united state of the public mind” *(Heath*v. *Heath, supra,*433) demands that the parties should not be bound by the marriage contract.

In the absence of any allegation in the petition that the defendant entered into the marriage relation with a secret intent not to consummate it, in which case annulment could be granted *(Babis*
      *340v. *Babis,*75 A. (2d) 580, Del. Superior Court; *Anders*v. *Anders,*224 Mass. 438), the petition is

*Dismissed nisi.*

All concurred.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Veterans Affairs

The Department of Veterans Affairs (VA) gives notice under Public Law 92-463 (Federal Advisory Committee Act) that the Advisory Committee on Former Prisoners of War (FPOW) has scheduled a meeting for October 16-18, 2006, in room 2452, at the Jesse Brown Medical Center, 820 S. Damen Avenue, Chicago, Illinois. The meeting will be from 9 a.m. to 4 p.m. each day. The meeting is open to the public.

The purpose of the Committee is to advise the Secretary of Veterans Affairs on the administration of benefits under title 38, United States Code, for veterans who are former prisoners of war, and to make recommendations on the needs of such veterans for compensation, health care, and rehabilitation.

On October 16, the meeting will include an introduction of Committee members, remarks from dignitaries, a review of Committee reports, an update of Committee activities, and time for FPOW veterans and/or the public to address the Committee. On October 17, the Committee will receive reports from the Veterans Health Administration and the Veterans Benefits Administration. The Committee will also get an update from the Robert E. Mitchell Center for Prisoner of War Studies. On October 18, the Committee's medical and administrative work groups will meet to discuss their activities and report back to the Committee. Additionally, the Committee will review issues discussed throughout the meeting to compile a report to be sent to the Secretary.

Members of the public may ask questions or submit written statements for review by the Committee in advance of the meeting to Ms. Linda Piquet, Compensation and Pension Service (21), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420.

Dated: September 15, 2006.

By Direction of the Secretary.

E. Philip Riggin,

Committee Management Officer.

[FR Doc. 06-8104 Filed 9-21-06; 8:45 am]

BILLING CODE 8320-01-M
Exhibit 10.5


 


FOLEY TRASIMENE ACQUISITION CORP. II

1701 Village Center Circle

Las Vegas, NV 89134

[●], 2020


 


Cannae Holdings, Inc.

1701 Village Center Circle

Las Vegas, NV 89134


 


Ladies and Gentlemen:


 


This letter will confirm our agreement that,
commencing on the effective date (the “Effective Date”) of the registration statement (the “Registration
Statement”) for the initial public offering (the “IPO”) of the securities of Foley Trasimene
Acquisition Corp. II (the “Company”) and continuing until the earlier of (i) the completion by the Company
of an initial business combination or (ii) the Company’s liquidation (in each case as described in the Registration Statement)
(such earlier date hereinafter referred to as the “Termination Date”), Cannae Holdings, Inc. (“Cannae
Holdings”) shall take steps directly or indirectly to make available to the Company certain office space, secretarial
and administrative services as may be required by the Company from time to time, situated at 1701 Village Center Circle, Las Vegas,
NV 89134 (or any successor location). In exchange therefore, the Company shall pay Cannae Holdings a sum of $5,000 per month, respectively,
on the Effective Date and continuing monthly thereafter until the Termination Date. Cannae Holdings hereby agrees that it does
not have any right, title, interest or claim of any kind in or to any monies that may be set aside in a trust account (the “Trust
Account”) that may be established upon the consummation of the IPO (the “Claim”) and hereby
waives any Claim it may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with the
Company and will not seek recourse against the Trust Account for any reason whatsoever.


 


	 	Very truly yours,
	 	 
	 	FOLEY TRASIMENE ACQUISITION CORP. II




 


	 	By:	 
	 	 	Name:	Michael L. Gravelle
	 	 	Title:	General Counsel and Corporate Secretary



 


AGREED TO AND ACCEPTED BY:


 


CANNAE HOLDINGS, INC.


 


	By:	 	 
	 	Name:	 
	 	Title:
2023 COPS Anti-Methamphetamine Program (CAMP) Awards 

State Recipient Award Amount 

Colorado Colorado Department of Public Safety $1,968,832 

Indiana Indiana State Police $2,000,000 

Kentucky Kentucky Department of State Police $1,388,315 

Louisiana Louisiana Department of State Police $2,000,000 

Mississippi Mississippi Department of Public Safety $1,615,716 

Missouri Missouri Department of Public Safety $1,200,000 

New York New York State Police $1,866,474 

Ohio Attorney General of Ohio $1,000,000 

Pennsylvania Pennsylvania Department of State Police $1,941,620 

Total number of awards 9 

TOTAL AMOUNT OF 2023 CAMP AWARDS $14,980,957
[Federal Register Volume 71, Number 18 (Friday, January 27, 2006)]
[Notices]
[Page 4598]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 06-774]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of General Medical Sciences; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as 
amended. The grant applications and the discussions could disclose 
confidential trade secrets or commercial property such as patentable 
material, and personal information concerning individuals associated 
with the grant applications, the disclosure of which would constitute a 
clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel MARC Post-Baccalaureate Research 
Education Program (PREP).
    Date: February 17, 2006.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Holiday Inn Select Bethesda, 8120 Wisconsin Avenue, 
Bethesda, MD 20814.
    Contact Person: Helen R. Sunshine, PhD, Chief, Office of 
Scientific Review, National Institute of General Medical Sciences, 
National Institutes of Health, Natcher Building, Room 3AN12F, 
Bethesda, MD 20892, 301-594-2881, <a href="/cdn-cgi/l/email-protection#3a494f5449525354527a54535d574914545352145d554c"><span class="__cf_email__" data-cfemail="9feceaf1ecf7f6f1f7dff1f6f8f2ecb1f1f6f7b1f8f0e9">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, 
Minority Biomedical Research Support; 93.821, Cell Biology and 
Biophysics Research; 93.859, Pharmacology, Physiology, and 
Biological Chemistry Research; 93.862, Genetics and Developmental 
Biology Research; 93.88, Minority Access to Research Careers; 93.96, 
Special Minority Initiatives, National Institutes of Health, HHS)

    Dated: January 19, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-774 Filed 1-26-06; 8:45 am]
BILLING CODE 1140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
§ 29.101 How will the Service conduct an initial review? ( a ) Within 30 calendar days of receipt of your application, the Service will notify you in writing that one of the following situations exists: ( 1 ) Your application is complete, and the Service will begin formal review;
( 2 ) Your application does not meet the information requirements, in which case we will identify the additional information required to be submitted before the Service will be able to conduct formal review of your application; or
( 3 ) More time is necessary to complete the review, in which case the Service will provide the amount of additional time reasonably needed along with a justification.
( b ) If you submit additional information as requested under paragraph (a)(2) of this section, and the Service determines that you have met all applicable information requirements, the Service will notify you within 30 calendar days from receipt of the additional information that either: ( 1 ) Your application is complete, and the Service will begin formal review; or
( 2 ) More time is necessary to complete the initial review, in which case the Service will provide the amount of additional time reasonably needed along with a justification.
Case 16-29181 Doc 1 Filed 09/13/16 Entered 09/13/16 13:27:06 Desc Main

 Document Page 1 of 9
Case 16-29181 Doc 1 Filed 09/13/16 Entered 09/13/16 13:27:06 Desc Main

 Document Page 2 of 9
Case 16-29181 Doc 1 Filed 09/13/16 Entered 09/13/16 13:27:06 Desc Main

 Document Page 3 of 9
Case 16-29181 Doc 1 Filed 09/13/16 Entered 09/13/16 13:27:06 Desc Main

 Document Page 4 of 9
Case 16-29181 Doc 1 Filed 09/13/16 Entered 09/13/16 13:27:06 Desc Main

 Document Page 5 of 9
Case 16-29181 Doc 1 Filed 09/13/16 Entered 09/13/16 13:27:06 Desc Main

 Document Page 6 of 9
Case 16-29181 Doc 1 Filed 09/13/16 Entered 09/13/16 13:27:06 Desc Main

 Document Page 7 of 9
Case 16-29181 Doc 1 Filed 09/13/16 Entered 09/13/16 13:27:06 Desc Main

 Document Page 8 of 9
Case 16-29181 Doc 1 Filed 09/13/16 Entered 09/13/16 13:27:06 Desc Main

 Document Page 9 of 9
EXHIBIT 4.5


SECOND AMENDMENT TO THE 
1999 STOCK INCENTIVE PLAN OF 
TARO PHARMACEUTICAL INDUSTRIES LTD.


     THIS SECOND AMENDMENT is made effective August 5, 2004, by TARO PHARMACEUTICAL INDUSTRIES LTD. (the “Company”), a corporation organized and existing under the laws of the Country of Israel.


W I T N E S S E T H:


     WHEREAS, the Company maintains the 1999 Stock Incentive Plan of Taro Pharmaceutical Industries Ltd. (the “Plan”), which was adopted by the Board of Directors of the Company on March 10, 1999, and approved be the stockholders of the Company on July 20, 1999.


     WHEREAS, the Company desires to amend the Plan to allow the grant of stock options to the Company’s “Identified Public Directors”, as such term is defined under the Israel Companies Law.


     WHEREAS, the Company’s shareholders, at the Annual General Meeting held on August 5, 2004, approved a resolution to amend the Plan to allow for the grant of stock options to Identified Public Directors as provided by new regulations issued under the Israel Companies Law.


     NOW, THEREFORE, the Plan is hereby amended, effective as of August 5, 2004, as follows:


	     	1.	     	By deleting from the first sentence of the last sub-paragraph of paragraph 4 the phrase “(other than an Identified Public Director)”.
		 
		2.	 	By deleting paragraph 20(e) in its entirety and substituting therefore “[Reserved]”.
		 
		3.		By deleting from paragraph 20(g) the phrase “and is not an Identified Public Director”.





     Except as specifically amended hereby, the Plan shall remain in full force and effect as prior to this Second Amendment.


[Remainder of page left intentionally blank]








     IN WITNESS WHEREOF, the Company has caused this Second Amendment to be executed, effective as of the day and year first above written.



		TARO PHARMACEUTICAL INDUSTRIES LTD. 
		 
		By: /s/ Kevin Connelly
		 
		Title: Senior Vice President & Chief Financial Officer
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Multidisciplinary Clinical Research Centers.                    

*Date:*                         October 18-19, 2006.                    

*Time:*                         6:30 p.m. to 5 p.m.                              ( print page 55203)    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.                    

*Contact Person:*                         Michael L. Bloom, PhD, Scientific Review Administrator, EP Review Branch, NIH-NIAMS Institute, One Democracy Plaza, Room 820, MSC 4872, 6701 Democracy Blvd, Bethesda, MD 20892-4872, 301-594-4953,                         *Michael_Bloom@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: September 13, 2006.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 06-7915  Filed 9-20-06; 8:45 am]

BILLING CODE 4140-01-M
**Exhibit 23.1**

 

**INDEPENDENT AUDITORS’ CONSENT**

 

We consent to the incorporation by reference in Registration Statement Nos: 333-61054, 333-43790, and 333-112361, each on Form S-3, andRegistration Statement Nos. 333-82283 and 333-16935 each on Form S-8, of our report dated March 26, 2004 on the consolidated financial statements of BriteSmile Inc. for the years ended December 27, 2003 and December 28, 2002, appearing in thisAnnual Report on Form 10-K of BriteSmile Inc. for the year ended December 27, 2003. 

 

 

/s/ Deloitte & Touche LLP 

 

 

Oakland, California 

March 26, 2004
Exhibit
      32.2





Certification
      Pursuant to 18 U.S.C. Section 1350 As Adopted Pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002








I,
      Colin Baird, Chief Financial Officer of Australian Forest Industries (the
      "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
      18 U.S.C. Section 1350, that:





(1)           the
      Quarterly Report on Form 10-QSB of the Company for the quarter ended September
      30, 2007 (the "Report") fully complies with the requirements of Section 13(a)
      or
      15(d) of the Securities Exchange Act of 1934, as amended; and





(2)           the
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the Company.








Date:November
      16,
      2007





/s/
      Colin Baird


Colin
      Baird


Chief
      Financial Officer
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 5164 Introduced in Senate (IS)]

<DOC>

118th CONGRESS
  2d Session
                                S. 5164

     To extend the temporary scheduling order for fentanyl-related 
                              substances.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                           September 25, 2024

 Mr. Grassley (for himself, Ms. Hassan, Mr. Cornyn, Mrs. Shaheen, Ms. 
Cortez Masto, Mr. Kennedy, and Ms. Klobuchar) introduced the following 
    bill; which was read twice and referred to the Committee on the 
                               Judiciary

_______________________________________________________________________

                                 A BILL

 
     To extend the temporary scheduling order for fentanyl-related 
                              substances.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Temporary Extension of Fentanyl 
Scheduling Act of 2024''.

SEC. 2. EXTENSION OF TEMPORARY ORDER FOR FENTANYL-RELATED SUBSTANCES.

    Section 2 of the Temporary Reauthorization and Study of the 
Emergency Scheduling of Fentanyl Analogues Act (Public Law 116-114; 134 
Stat. 103) is amended by striking ``December 31, 2024'' and inserting 
``December 31, 2025''.
                                 <all>
```